沐鸣娱乐-沐鸣2娱乐平台注册登录网站

Research and Development 沐鸣APP

沐鸣娱乐沐鸣赞助沐鸣游戏沐鸣体育赛事沐鸣发表

发表时间：2024/07/23 来源：The New England Journal of Medicine

Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
发表时间：2024/05/13 来源：EHA 2024 Congress Poster Presentation

Inaticabtagene Autoleucel (CNCT19) in Relapased and Refreactory B-cell Lymphoma: Results of a Phase I Clinical Trial
发表时间：2024/03/24 来源：Journal for ImmunoTherapy of Cancer

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory Large B-cell Lymphoma
发表时间：2023/11/01 来源：Blood - 2023 ASH Annual Meeting Abstract

Developing “Off-the-Shelf” CLL1 CAR-DNT Therapeutics for the R/R Acute Myeloid Leukemia
发表时间：2022/11/14 来源：Blood - 2022 ASH Annual Meeting Abstract

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China
发表时间：2022/11/14 来源：Blood - 2022 ASH Annual Meeting Abstract

Long-Term Activity of combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

1 2 3

我们的目标专注细胞治疗领航健康未来